Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Histakon - Philippines FDA Drug Approval Details

Approvals/Philippines FDA/Histakon

Approved

STANDARD

Histakon

Magbro Healthcare Pvt. Ltd.🇵🇭 Food and Drug Administration - Philippines

Approval Date: Jul 14, 2025
Approval ID: 864e77fbb67dc76c
Company: Magbro Healthcare Pvt. Ltd.
Type: Standard

Approval Details

Approval Id: 864e77fbb67dc76c
Drug Approval Philippines Name: Histakon
Product Name: Histakon
Registration Number: DRP-13706
Brand Name: Histakon
Generic Name: Betahistine hydrochloride
Dosage Form: Tablet
Dosage Strength: 24 mg
Manufacturer: Magbro Healthcare Pvt. Ltd.
Trader: India
Distributor: Pharmakon Biotec Inc.
Issuance Date: 29 March 2023
Expiry Date: 29 March 2028
Classification: Prescription Drug (RX)

Active Ingredients

Approved

Quick Info

Agency

Philippines FDA

Country

🇵🇭

Approval Date

Jul 14, 2025

Approval ID

864e77fbb67dc76c

Type

Standard

Back to Philippines FDA Approvals